Parkinson's disease psychosis: presentation, diagnosis and management

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov. Disord. 29(13), 1583–1590 (2014).
  MedlineGoogle Scholar
• 2 Elbaz A, Bower JH, Maraganore DM et al. Risk tables for parkinsonism and Parkinson's disease. J. Clin. Epidemiol. 55(1), 25–31 (2002).
  MedlineGoogle Scholar
• 3 Aarsland D, Larsen JP, Cummings JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease. Arch. Neurol. 56(5), 595–601 (1999).
  Medline CASGoogle Scholar
• 4 Lee AH, Weintraub D. Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms. Mov. Disord. 27(7), 858–863 (2012).
  MedlineGoogle Scholar
• 5 Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 70(6), 734–738 (2001).
  Medline CASGoogle Scholar
• 6 Weintraub D, Morales KH, Duda KE, Moberg PJ, Stern MB. Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease. Parkinsonism Relat. Disord. 12(7), 427–431 (2006).
  MedlineGoogle Scholar
• 7 Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch. Neurol. 53(12), 1265–1268 (1996).
  Medline CASGoogle Scholar
• 8 Giladi N, Treves TA, Paleacu D et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J. Neural. Transm. (Vienna) 107(1), 59–71 (2000).
  Medline CASGoogle Scholar
• 9 Mack J, Rabins P, Anderson K et al. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am. J. Geriatr. Psychiatry 20(2), 123–132 (2012).
  MedlineGoogle Scholar
• 10 Factor SA, Steenland NK, Higgins DS et al. Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease. Mov. Disord. 26(12), 2190–2195 (2011).
  MedlineGoogle Scholar
• 11 Gama RL, de Bruin VMS, de Bruin PFC et al. Risk factors for visual hallucinations in patients with Parkinson's disease. Neurol. Res. 37(2), 112–116 (2015).
  MedlineGoogle Scholar
• 12 Fénelon G, Soulas T, Zenasni F, de Langavant LC. The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov. Disord. 25(6), 763–766 (2010).
  MedlineGoogle Scholar
• 13 Auyeung M, Tsoi TH, Mok V et al. Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson's disease patients. J. Neurol. Neurosurg. Psych. 83(6), 607–611 (2012).
  MedlineGoogle Scholar
• 14 Forsaa EB, Larsen JP, Wentzel-Larsen T et al. A 12-year population-based study of psychosis in Parkinson disease. Arch. Neurol. 67(8), 996–1001 (2010).
  MedlineGoogle Scholar
• 15 Naimark D, Jackson E, Rockwell E, Jeste DV. Psychotic symptoms in Parkinson's disease patients with dementia. J. Am. Geriatr. Soc. 44(3), 296–299 (1996).
  Medline CASGoogle Scholar
• 16 Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ et al. Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. Parkinsonism Relat. Disord. 21(6), 629–634 (2015).
  MedlineGoogle Scholar
• 17 Aarsland D, Brønnick K, Ehrt U et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J. Neurol. Neurosurg. Psych. 78(1), 36–42 (2007).
  Medline CASGoogle Scholar
• 18 Kulisevsky J, Pagonabarraga J, Pascual-Sedano B et al. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov. Disord. 23(13), 1889–1896 (2008).
  MedlineGoogle Scholar
• 19 Pagonabarraga J, Martinez-Horta S, de Bobadilla RM et al. Minor hallucinations occur in drug-naïve Parkinson's disease patients, even from the premotor phase. Mov. Disord. 31(1), 45–52 (2016). •• Interesting longitudinal study that highlights the common occurrence of minor phenomena in early Parkinson's disease and their evolution over time.
  MedlineGoogle Scholar
• 20 Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 123(Pt 4), 733–745 (2000).
  MedlineGoogle Scholar
• 21 Amar BR, Yadav R, Janardhan Reddy YC, Pal PK. A clinical profile of patients with Parkinson's disease and psychosis. Ann. Indian Acad. Neurol. 17(2), 187–192 (2014).
  Medline CASGoogle Scholar
• 22 Papapetropoulos S, Katzen H, Schrag A et al. A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease. BMC Neurol. 8, 21 (2008).
  MedlineGoogle Scholar
• 23 Goetz CG, Wuu J, Curgian L, Leurgans S. Age-related influence on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov. Disord. 21(2), 267–270 (2006).
  MedlineGoogle Scholar
• 24 Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 51(3), 811–814 (1998).
  Medline CASGoogle Scholar
• 25 Pacchetti C, Manni R, Zangaglia R et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov. Disord. 20(11), 1439–1448 (2005).
  MedlineGoogle Scholar
• 26 Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J. Neurol. Neurosurg. Psych. 70(6), 727–733 (2001).
  Medline CASGoogle Scholar
• 27 Rana AQ, Siddiqui I, Zangeneh M, Fattah A, Awan N, Yousuf MS. Predicting treatment-seeking for visual hallucinations among Parkinson's disease patients. Psychiatry Clin. Neurosci. 67(7), 509–516 (2013).
  MedlineGoogle Scholar
• 28 Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J. Neurol. Neurosurg. Psych. 64(4), 533–535 (1998).
  Medline CASGoogle Scholar
• 29 Llorca PM, Pereira B, Jardri R et al. Hallucinations in schizophrenia and Parkinson's disease: an analysis of sensory modalities involved and the repercussion on patients. Sci. Rep. 6, 38152 (2016).
  Medline CASGoogle Scholar
• 30 Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 63(2), 293–300 (2004).
  Medline CASGoogle Scholar
• 31 Riedel O, Klotsche J, Spottke A et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J. Neurol. 257(7), 1073–1082 (2010).
  MedlineGoogle Scholar
• 32 Solla P, Cannas A, Ibba FC et al. Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease. J. Neurol. Sci. 323(1–2), 33–39 (2012).
  MedlineGoogle Scholar
• 33 Verbaan D, van Rooden SM, Visser M, Marinus J, Emre M, van Hilten JJ. Psychotic and compulsive symptoms in Parkinson's disease. Mov. Disord. 24(5), 738–744 (2009).
  MedlineGoogle Scholar
• 34 Poletti M, Perugi G, Logi C et al. Dopamine agonists and delusional jealousy in Parkinson's disease: a cross-sectional prevalence study. Mov. Disord. 27(13), 1679–1682 (2012).
  MedlineGoogle Scholar
• 35 Roane DM, Rogers JD, Robinson JH, Feinberg TE. Delusional misidentification in association with parkinsonism. J. Neuropsychiatry Clin. Neurosci. 10(2), 194–198 (1998).
  Medline CASGoogle Scholar
• 36 Stewart JT. Frégoli syndrome associated with levodopa treatment. Mov. Disord. 23(2), 308–309 (2008).
  MedlineGoogle Scholar
• 37 Pagonabarraga J, Llebaria G, García-Sánchez C, Pascual-Sedano B, Gironell A, Kulisevsky J. A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia. Mov. Disord. 23(3), 443–448 (2008).
  MedlineGoogle Scholar
• 38 Diagnostic and Statistical Manual of Mental Disorders (4th Edition). American Psychiatric Association, Washington, DC, USA (1994).
  Google Scholar
• 39 Ravina B, Marder K, Fernandez HH et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov. Disord. 22(8), 1061–1068 (2007). • Excellent description of the proposed diagnostic criteria for Parkinson's disease psychosis.
  MedlineGoogle Scholar
• 40 Gordon PC, Rocha MS, Kauark RG et al. Validation of the National Institute of Neurological Disorders and Stroke criteria for psychosis in Parkinson disease. Am. J. Geriatr. Psychiatry 25(1), 73–80 (2017).
  MedlineGoogle Scholar
• 41 Gordon PC, Kauark RB, Costa CD, de Oliveira MO, Godinho FL, Rocha MS. Clinical implications of the National Institute of Neurological Disorders and Stroke criteria for diagnosing psychosis in Parkinson's disease. J. Neuropsych. Clin. Neurosci. 28(1), 26–31 (2016).
  MedlineGoogle Scholar
• 42 Miyasaki JM, Shannon K, Voon V et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66(7), 996–1002 (2006).
  Medline CASGoogle Scholar
• 43 Fernandez HH, Aarsland D, Fénelon G et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Task force report. Mov. Disord. 23(4), 484–500 (2008).
  MedlineGoogle Scholar
• 44 Voss TS, Bahr D, Cummings J, Mills R, Ravina B, Williams H. Performance of a shortened scale for assessment of positive symptoms for Parkinson's disease psychosis. Parkinsonism Relat. Disord. 19(3), 295–299 (2013).
  MedlineGoogle Scholar
• 45 Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, Brotchie JM. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch. Neurol. 63(9), 1343–1344 (2006).
  MedlineGoogle Scholar
• 46 Chang A, Fox S. Psychosis in Parkinson's disease: epidemiology, pathophysiology, and management. Drugs 76(11), 1093–1118 (2016).
  Medline CASGoogle Scholar
• 47 Goldman JG. New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. Parkinsons Dis. 2011, 675630 (2011).
  MedlineGoogle Scholar
• 48 Voon V, Napier TC, Frank MJ et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. Lancet Neurol. 16(3), 238–250 (2017).
  MedlineGoogle Scholar
• 49 Goetz CG, Pappert EJ, Blasucci LM et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50(2), 515–517 (1998).
  Medline CASGoogle Scholar
• 50 Dotchin CL, Jusabani A, Walker RW. Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania. Parkinsonism Relat. Disord. 15(6), 457–460 (2009).
  Medline CASGoogle Scholar
• 51 de la Riva P, Smith K, Xie SX, Weintraub D. Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology 83(12), 1096–1103 (2014).
  MedlineGoogle Scholar
• 52 Weintraub D, Simuni T, Caspell-Garcia C et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov. Disord. 30(7), 919–927 (2015).
  MedlineGoogle Scholar
• 53 Ffytche DH, Pereira JB, Ballard C, Chaudhuri KR, Weintraub D, Aarsland D. Risk factors for early psychosis in PD: insights from the Parkinson's progression markers initiative. J. Neurol. Neurosurg. Psych. 88(4), 325–331 (2017).
  MedlineGoogle Scholar
• 54 Merims D, Shabtai H, Korczyn AD, Peretz C, Weizman N, Giladi N. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J. Neural Transm. (Vienna) 111(10–11), 1447–1553 (2004).
  Medline CASGoogle Scholar
• 55 Papapetropoulos S, Argyriou AA, Ellul J. Factors associated with drug-induced visual hallucinations in Parkinson's disease. J. Neurol. 252(10), 1223–1228 (2005).
  MedlineGoogle Scholar
• 56 Yoritaka A, Shimo Y, Takanashi M et al. Motor and non-motor symptoms of 1453 patients with Parkinson's disease: prevalence and risks. Parkinsonism Relat. Disord. 19(8), 725–731 (2013).
  MedlineGoogle Scholar
• 57 Ecker D, Unrath A, Kassubek J, Sabolek M. Dopamine agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study. BMC Neurol. 9, 23 (2009).
  MedlineGoogle Scholar
• 58 Morgante L, Colosimo C, Antonini A et al. Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. J. Neurol. Neurosurg. Psych. 83(1), 76–82 (2012).
  MedlineGoogle Scholar
• 59 Goetz CG, Ouyang B, Negron A, Stebbins GT. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology 75(2), 1773–1779 (2010). • Highlights the relationship between hallucinations and sleep abnormalities.
  MedlineGoogle Scholar
• 60 Zahodne LB, Fernandez HH. A review of the pathophysiology and treatment of psychosis in Parkinson's disease. Drugs Aging 25(8), 665–682 (2008).
  Medline CASGoogle Scholar
• 61 Sawada H, Oeda T, Yamamoto K et al. Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study. BMC Neurol. 13, 145 (2013).
  MedlineGoogle Scholar
• 62 Urwyler P, Nef T, Killen A et al. Visual complaints and visual hallucinations in Parkinson's disease. Parkinsonism Relat. Disord. 20(3), 318–322 (2014).
  MedlineGoogle Scholar
• 63 Wakamori T, Agari T, Yasuhara T et al. Cognitive functions in Parkinson's disease: relation to disease severity and hallucination. Parkinsonism Relat. Disord. 20(4), 415–420 (2014).
  MedlineGoogle Scholar
• 64 Leroi I, Pantula H, McDonald K, Harbishettar V. Neuropsychiatric symptoms in Parkinson's disease with mild cognitive impairment and dementia. Parkinsons Dis. 2012, 308097 (2012).
  MedlineGoogle Scholar
• 65 Guo X, Song W, Chen K et al. Disease duration-related differences in non-motor symptoms: a study of 616 Chinese Parkinson's disease patients. J. Neurol. Sci. 330(1–2), 32–37 (2013).
  MedlineGoogle Scholar
• 66 Zhou MZ, Gan J, Wei YR, Ren XY, Chen W, Liu ZG. The association between non-motor symptoms in Parkinson's disease and age at onset. Clin. Neurol. Neurosurg. 115(10), 2103–2107 (2013).
  MedlineGoogle Scholar
• 67 Poletti M, Lucetti C, Baldacci F, Del Dotto P, Bonuccelli U. Concomitant development of hypersexuality and delusional jealousy in patients with Parkinson's disease: a case series. Parkinsonism Relat. Disord. 20(11), 1290–1292 (2014).
  MedlineGoogle Scholar
• 68 Ruffmann C, Calboli FC, Bravi I et al. Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases. Neuropathol. Appl. Neurobiol. 42(5), 436–450 (2016).
  Medline CASGoogle Scholar
• 69 Jacobson SA, Morshed T, Dugger BN et al. Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. Parkinsonism Relat. Disord. 20(9), 1009–1114 (2014).
  MedlineGoogle Scholar
• 70 Ffytche DH, Creese B, Politis M et al. The psychosis spectrum in Parkinson disease. Nat. Rev. Neurol. 13(2), 81–95 (2017).
  MedlineGoogle Scholar
• 71 Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol. 4(10), 605–610 (2005).
  MedlineGoogle Scholar
• 72 Hepp DH, Ruiter AM, Galis Y et al. Pedunculopontine cholinergic cell loss in hallucinating Parkinson disease patients but not in dementia with Lewy bodies patients. J. Neuropathol. Exp. Neurol. 72(12), 1162–1170 (2013).
  Medline CASGoogle Scholar
• 73 Liu AK, Chang RC, Pearce RK, Gentleman SM. Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease. Acta Neuropathol. 129(4), 527–540 (2015).
  Medline CASGoogle Scholar
• 74 Burn D, Emre M, McKeith I et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov. Disord. 21(11), 1899–1907 (2006).
  MedlineGoogle Scholar
• 75 Huot P, Fox SH. The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Exp. Brain Res. 230(4), 463–476 (2013).
  Medline CASGoogle Scholar
• 76 Stahl SM. Parkinson's disease psychosis as a serotonin–dopamine imbalance syndrome. CNS Spectr. 21(5), 355–359 (2016).
  MedlineGoogle Scholar
• 77 Sadzot B, Baraban JM, Glennon RA et al. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology (Berl). 98(4), 495–499 (1989).
  Medline CASGoogle Scholar
• 78 Oz M, Zhang L, Rotondo A, Sun H, Morales M. Direct activation by dopamine of recombinant human 5-HT1A receptors: comparison with human 5-HT2C and 5-HT3 receptors. Synapse 50(4), 303–313 (2003).
  Medline CASGoogle Scholar
• 79 Kusumi I, Boku S, Takahashi Y. Psychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesis. Psychiatry Clin. Neurosci. 69(5), 243–258 (2015).
  Medline CASGoogle Scholar
• 80 Nichols MJ, Hartlein JM, Eicken MG, Racette BA, Black KJ. A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease. F1000 Res. 2, 150 (2013).
  MedlineGoogle Scholar
• 81 Breier A, Sutton VK, Feldman PD et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol. Psych. 52(5), 438–445 (2002).
  Medline CASGoogle Scholar
• 82 Arnulf I, Bonnet AM, Damier P et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 55(2), 281–288 (2000).
  Medline CASGoogle Scholar
• 83 St Louis EK, Boeve AR, Boeve BF. REM sleep behavior disorder in Parkinson's disease and other synucleinopathies. Mov. Disord. 32(5), 645–658 (2017).
  Medline CASGoogle Scholar
• 84 Goetz CG, Stebbins GT, Ouyang B. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov. Disord. 26(12), 2196–2200 (2011).
  MedlineGoogle Scholar
• 85 Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of “benign hallucinations” in Parkinson disease. Arch. Neurol. 63(5), 713–716 (2006).
  MedlineGoogle Scholar
• 86 Goetz CG, Fan W, Leurgans S. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: positive impact on long-term worsening. Mov. Disord. 23(11), 1541–1545 (2008).
  MedlineGoogle Scholar
• 87 Llebaria G, Pagonabarraga J, Martínez-Corral M et al. Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Mov. Disord. 25(16), 2785–2791 (2010).
  MedlineGoogle Scholar
• 88 Factor SA, Scullin MK, Sollinger AB et al. Cognitive correlates of hallucinations and delusions in Parkinson's disease. J. Neurol. Sci. 347(1–2), 316–321 (2014).
  MedlineGoogle Scholar
• 89 Factor SA, McDonald WM, Goldstein FC. The role of neurotransmitters in the development of Parkinson's disease-related psychosis. Eur. J. Neurol. 24(10), 1244–1255 (2017).
  Medline CASGoogle Scholar
• 90 Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43(11), 2227–2229 (1993).
  Medline CASGoogle Scholar
• 91 Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 45(4), 669–671 (1995).
  Medline CASGoogle Scholar
• 92 de lau LM, Verbaan D, Marinus J, van Hilten JJ. Survival in Parkinson's disease. Relation with motor and non-motor features. Parkinsonism Relat. Disord. 20(6), 613–616 (2014).
  MedlineGoogle Scholar
• 93 Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease? A prospective population-based long-term study. Neurology 75(14), 1270–1276 (2010).
  Medline CASGoogle Scholar
• 94 Weintraub D, Chiang C, Kim HM et al. Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol. 73(5), 535–541 (2016). • Highlights the potential increased mortality risk associated with antipsychotic use in Parkinson's disease.
  MedlineGoogle Scholar
• 95 Weintraub D, Chiang C, Kim HM et al. Antipsychotic use and physical morbidity in Parkinson disease. Am. J. Geriatr. Psychiatry 25(7), 697–705 (2017).
  MedlineGoogle Scholar
• 96 Wand AP, Peisah C. Managing psychosis in Parkinson's disease without drugs. Neurodegener. Dis. Manag. 5(4), 271–274 (2015).
  Google Scholar
• 97 Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson's disease. Mov. Disord. 18(7), 831–832 (2003).
  MedlineGoogle Scholar
• 98 Thomsen TR, Panisset M, Suchowersky O, Goodridge A, Mendis T, Lang AE. Impact of standard of care for psychosis in Parkinson disease. J. Neurol. Neurosurg. Psych. 79(12), 1413–1415 (2008).
  Medline CASGoogle Scholar
• 99 Oh YS, Kim JS, Lee PH. Effect of rivastigmine on behavioral and psychiatric symptoms of Parkinson's disease dementia. J. Mov. Disord. 8(2), 98–102 (2015).
  MedlineGoogle Scholar
• 100 Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci. 23(1), 41–43 (2002).
  Medline CASGoogle Scholar
• 101 Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson's disease: a randomised, double-blind, placebo controlled crossover study. J. Neurol. Neurosurg. Psych. 76(7), 934–939 (2005).
  Medline CASGoogle Scholar
• 102 Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J. Neurol. Neurosurg. Psych. 72(6), 708–712 (2002).
  Medline CASGoogle Scholar
• 103 Sarva H, Henchcliffe C. Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis. Ther. Adv. Neurol. Disord. 9(6), 462–473 (2016).
  Medline CASGoogle Scholar
• 104 Ellis T, Cudkowicz ME, Sexton PM, Grodwon JH. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J. Neuropsych. Clin. Neurosci. 12(3), 364–369 (2000).
  Medline CASGoogle Scholar
• 105 Marsh L, Lyketsos C, Reich SG. Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia. Psychosomatics 42(6), 477–481 (2001).
  Medline CASGoogle Scholar
• 106 Giménez-Roldán S, Mateo D, Navarro E, Ginés MM. Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis. Parkinsonism Relat. Disord. 7(2), 121–127 (2001).
  Medline CASGoogle Scholar
• 107 Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55(6), 789–794 (2000).
  Medline CASGoogle Scholar
• 108 Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin. Neuropharmacol. 27(1), 4–5 (2004).
  Medline CASGoogle Scholar
• 109 Friedman JH, Berman RM, Goetz CG et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov. Disord. 21(12), 2078–2081 (2006).
  MedlineGoogle Scholar
• 110 The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. J. Med. 340(10), 757–763 (1999).
  Google Scholar
• 111 The French Clozapine Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 353(9169), 2041–2042 (1999).
  MedlineGoogle Scholar
• 112 Hack N, Fayad SM, Monari EH et al. An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting. PLoS ONE 9(3), e91545 (2014).
  MedlineGoogle Scholar
• 113 Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov. Disord. 19(7), 831–833 (2004).
  MedlineGoogle Scholar
• 114 Klein C, Gordon J, Pollak L, Rabey JM. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin. Neuropharmacol. 26(1), 8–11 (2003).
  Medline CASGoogle Scholar
• 115 Trosch RM, Friedman JH, Lannon MC et al. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov. Disord. 13(3), 377–382 (1998).
  Medline CASGoogle Scholar
• 116 Pollak P, Tison F, Rascol O et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomized, placebo controlled study with open follow up. J. Neurol. Neurosurg. Psych. 75(5), 689–695 (2004).
  Medline CASGoogle Scholar
• 117 Prohorov T, Klein C, Miniovitz A, Dobronevsky E, Rabey JM. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J. Neurol. 253(2), 171–175 (2006).
  Medline CASGoogle Scholar
• 118 Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch. Neurol. 68(7), 899–904 (2011).
  MedlineGoogle Scholar
• 119 Klein C, Prokhorov T, Miniovich A, Dobronevsky E, Rabey JM. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin. Neuropharmacol. 29(4), 215–219 (2006).
  Medline CASGoogle Scholar
• 120 Juncos JL, Roberts VJ, Evatt ML et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov. Disord. 19(1), 29–35 (2004).
  MedlineGoogle Scholar
• 121 Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov. Disord. 17(4), 676–681 (2002).
  MedlineGoogle Scholar
• 122 Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin. Neuropharmacol. 29(6), 331–337 (2006).
  Medline CASGoogle Scholar
• 123 Morgante L, Epifanio A, Spina E et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin. Neuropharmacol. 27(4), 153–156 (2004).
  Medline CASGoogle Scholar
• 124 Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr. Dis. Treat. 5, 327–332 (2009).
  Medline CASGoogle Scholar
• 125 Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months’ duration. Mov. Disord. 22(3), 313–318 (2007).
  MedlineGoogle Scholar
• 126 Ondo WG, Tintner R, Voung KD et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov. Disord. 20(8), 958–963 (2005).
  MedlineGoogle Scholar
• 127 Kurlan R, Cummings J, Raman R et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 68(17), 1356–1363 (2007).
  Medline CASGoogle Scholar
• 128 Desmarais P, Massoud F, Filion J, Nguyen QD, Bajsarowicz P. Quetiapine for psychosis in Parkinson disease and neurodegenerative parkinsonian disorders: a systematic review. J. Geriatr. Psychiatry Neurol. 29(4), 227–236 (2016).
  MedlineGoogle Scholar
• 129 Fernandez HH, Okun MS, Rodriguez RL et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int. J. Neurosci. 119(12), 2196–2205 (2009).
  Medline CASGoogle Scholar
• 130 Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov. Disord. 18(5), 510–514 (2003).
  MedlineGoogle Scholar
• 131 Martinez-Ramirez D, Okun MS, Jaffee MS. Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists. Neurodegener. Dis. Manag. 6(4), 319–330 (2016).
  Google Scholar
• 132 Meltzer HY, Mills R, Revell S et al. Pimavanserin, a serotonin (2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 35(4), 881–892 (2010).
  Medline CASGoogle Scholar
• 133 Cummings J, Isaacson S, Mills R et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebo-controlled phase 3 trial. Lancet. 383(9916), 533–540 (2014). •• Pivotal Phase III trial of pimavanserin for Parkinson's disease psychosis.
  Medline CASGoogle Scholar
• 134 Combs BL, Cox AG. Update on the treatment of Parkinson's disease psychosis: role of pimavanserin. Neuropsychiatr. Dis. Treat. 13, 737–744 (2017).
  Medline CASGoogle Scholar
• 135 Yasue I, Matsunaga S, Kishi T, Fujita K, Iwata N. Serotonin 2A receptor inverse agonist as a treatment for Parkinson's disease psychosis: a systematic review and meta-analysis of serotonin 2A receptor negative modulators. J. Alzheimers Dis. 50(3), 733–740 (2016).
  Medline CASGoogle Scholar
• 136 Ballard C, Isaacson S, Mills R et al. Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis. J. Am. Med. Rid. Assoc. 16(10), 898.e1–898.e7 (2015).
  Google Scholar
• 137 Friedman JH. A retrospective study of pimavanserin use in a movement disorders clinic. Clin. Neuropharmacol. 40(4), 157–159 (2017).
  Medline CASGoogle Scholar
• 138 Friedman JH. Parkinson's disease psychosis 2010: a review article. Parkinsonism Relat. Disord. 16(9), 553–560 (2010).
  MedlineGoogle Scholar
• 139 Pahwa R, Davis T, Lyons K. Pimavanserin practice based recommendations. Parkinson's Foundation. www.parkinson.org/sites/default/files/Pimavanserin-PF.pdf.
  Google Scholar